|
More
Drug Screening
Research Library
|
|
The Jackson Laboratory
|
This pathways resource is designed to facilitate the discovery of new targeted therapies for several common human autoimmune diseases by highlighting the biological pathways they share and the most relevant mouse models and resources available for their study. Inside, you will find the following:
• Schematics of the genetic pathways common to rheumatoid arthritis, asthma, psoriasis, multiple ...
|
|
|
Cetero Research
|
A crucial element in the development of topical and transdermal drug products is evaluation of the percutaneous absorption of the active pharmaceutical ingredient (API). Generally, the goal for topical products is to maximize cutaneous delivery of the API, whereas for transdermal products the goal is to achieve a specific rate of absorption sufficient to achieve a systemic blood level within the ...
|
|
|
Covance
|
Conducting comprehensive metabolism studies has long been an essential component of a preclinical drug development program. However, numerous factors — including the increased development of protein-derived drugs and the expanded interest in the role of metabolites in safety assessment — are having a significant impact on the regulatory mandates, scope of studies and methodologies employed. In ...
|
|
|
BIOCIUS
|
The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more interest than those that simply shift the bottlenecks and necessitate new compromises in the discovery and development process.
|
|
|
Beckloff Associates
|
The U.S. Orphan Drug Act was signed into law in 1983 and for the first time, provided incentives for the pharmaceutical industry to develop drugs that otherwise had minimal commercial return on investment, but which are necessary, and often life-saving, for patients with rare diseases. The Orphan Drug Act is codified in 21 CFR Part 316.
There are approximately 6000 rare disorders affecting ...
|
|
|
|
